[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oruka Therapeutics Inc (ORKA)

Oruka Therapeutics Inc (ORKA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,313,159
  • Shares Outstanding, K 60,312
  • Annual Sales, $ 0 K
  • Annual Income, $ -105,430 K
  • EBIT $ -133 M
  • EBITDA $ -138 M
  • 60-Month Beta -0.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.91

Options Overview Details

View History
  • Implied Volatility 85.75% (+1.10%)
  • Historical Volatility 62.97%
  • IV Percentile 19%
  • IV Rank 16.97%
  • IV High 206.40% on 09/10/25
  • IV Low 61.08% on 05/19/26
  • Expected Move (DTE 8) 9.72 (9.05%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 70
  • Volume Avg (30-Day) 147
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 4,461
  • Open Int (30-Day) 4,172
  • Expected Range 97.68 to 117.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.59
  • Number of Estimates 5
  • High Estimate $-0.47
  • Low Estimate $-0.66
  • Prior Year $-0.55
  • Growth Rate Est. (year over year) -7.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
80.72 +33.05%
on 07/17/26
109.42 -1.84%
on 08/12/26
+20.61 (+23.75%)
since 07/10/26
3-Month
53.62 +100.30%
on 06/01/26
109.42 -1.84%
on 08/12/26
+42.75 (+66.13%)
since 05/12/26
52-Week
14.03 +665.50%
on 08/13/25
109.42 -1.84%
on 08/12/26
+93.45 (+669.89%)
since 08/12/25

Most Recent Stories

More News
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026...

ORKA : 107.40 (+2.60%)
Oruka's Psoriasis Trial Data Could Redefine What Investors Think They Own

Barchart Research What to Expect from ORKA Earnings ORKA Generated August 7, 2026 Current Price $98.82 EPS Estimate $$-0.49 Consensus Rating Strong Buy Average Move 7.23% Oruka's Psoriasis Trial Data Could...

ORKA : 107.40 (+2.60%)
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard...

ORKA : 107.40 (+2.60%)
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated...

ORKA : 107.40 (+2.60%)
Oruka's Psoriasis Data Already Priced In Unless the Quarterly Dosing Profile Surprises

Barchart Research What to Expect from ORKA Earnings ORKA Generated May 12, 2026 Current Price $64.65 EPS Estimate $$-0.52 Consensus Rating Strong Buy Average Move 7.44% Oruka's Psoriasis Data Already Priced...

ORKA : 107.40 (+2.60%)
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics...

ORKA : 107.40 (+2.60%)
Tech Earnings Optimism Powers Stocks Higher

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.12%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.01%. June E-mini...

ALK : 47.37 (-2.13%)
UAL : 125.12 (-0.94%)
AMAT : 548.15 (+4.29%)
SNDK : 1,344.29 (+5.76%)
VZ : 46.98 (-0.61%)
ADI : 384.43 (-0.23%)
TXN : 276.59 (-1.65%)
$IUXX : 29,742.60 (+0.74%)
ELV : 399.14 (+2.25%)
UNH : 405.59 (+0.85%)
ASML : 1,810.07 (+0.59%)
DPZ : 353.72 (-1.01%)
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics...

ORKA : 107.40 (+2.60%)
Stocks Slip as Higher Oil Prices Spur Inflation Concerns

The S&P 500 Index ($SPX ) (SPY ) today is down -0.12%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.30%. June E-mini S&P futures...

ALK : 47.37 (-2.13%)
UAL : 125.12 (-0.94%)
AMAT : 548.15 (+4.29%)
SNDK : 1,344.29 (+5.76%)
VZ : 46.98 (-0.61%)
ADI : 384.43 (-0.23%)
TXN : 276.59 (-1.65%)
$IUXX : 29,742.60 (+0.74%)
DPZ : 353.72 (-1.01%)
ZNU26 : 108-220 (+0.13%)
ESU26 : 7,777.75 (+0.09%)
NCLH : 18.92 (+1.18%)
Stocks Pressured by Higher Oil Prices

The S&P 500 Index ($SPX ) (SPY ) today is unchanged, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.10%. June E-mini S&P futures (ESM26...

AAPL : 302.25 (-0.87%)
CRWD : 221.78 (-0.05%)
VZ : 46.98 (-0.61%)
$SPX : 7,748.50 (+0.26%)
MU : 911.29 (+4.92%)
MANE : 109.05 (+0.09%)
$IUXX : 29,742.60 (+0.74%)
NQU26 : 29,836.25 (-0.06%)
DPZ : 353.72 (-1.01%)
QQQ : 723.70 (+0.73%)
CLU26 : 82.27 (-1.20%)
ZNU26 : 108-220 (+0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Oruka Therapeutics Inc. is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka Therapeutics Inc., formerly known as ARCA biopharma Inc., is based in WESTMINSTER, Colo.

See More

Key Turning Points

3rd Resistance Point 114.51
2nd Resistance Point 111.96
1st Resistance Point 109.68
Last Price 107.40
1st Support Level 104.85
2nd Support Level 102.31
3rd Support Level 100.03

See More

52-Week High 109.42
Last Price 107.40
Fibonacci 61.8% 72.98
Fibonacci 50% 61.72
Fibonacci 38.2% 50.47
52-Week Low 14.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.